Too right Musky. The sales team would have been building interest in and pre selling VascuCel for the last 6 months if not longer. I am not a champion sales person but even I know that this is how you "launch" a new product.
Unlike CardioCel (where we had a "cold" start) we are going into this with an experienced and incentivised sales team, sales targets, existing hospital accounts, established customer relationships and extensive data on safety and performance of the ADAPT process.
While we need to keep our expectations in check, with competitors having issues and our results continuing to be top notch, it's a great time to launch VascuCel. Exciting times ahead.
AHZ, page-303
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.010(0.08%) |
Mkt cap ! $257.6M | |||
| Open | High | Low | Value | Volume |
| $12.19 | $12.20 | $11.60 | $173.1K | 14.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9 | $11.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 28 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |